Tumor origin
HCC, cholangiocarcinoma, mixed tumor or metastasis must be clarified.
A hepatology-oncology review for liver tumors, separating hepatocellular carcinoma, cholangiocarcinoma and liver metastases while organizing liver function, viral hepatitis status, portal hypertension and previous local or systemic therapy.
“Liver cancer” can mean hepatocellular carcinoma, cholangiocarcinoma or metastases from another primary tumor. The file must clarify the origin because treatment logic and risk assessment are very different.
For primary liver cancer, liver function and portal hypertension can be as important as tumor size. The review therefore includes Child-Pugh-type information, bilirubin, albumin, INR, ascites and viral hepatitis context.
HCC, cholangiocarcinoma, mixed tumor or metastasis must be clarified.
Bilirubin, albumin, INR, platelets, ascites, encephalopathy and cirrhosis status are reviewed.
HBV/HCV history, antiviral therapy and viral load when available are included.
Number/size of lesions, portal vein thrombosis, vascular invasion and extrahepatic spread are documented.
Surgery, ablation, TACE/TARE, radiation, immunotherapy/targeted therapy or chemotherapy are summarized.
Jaundice, ascites, infection, bleeding risk and performance status are documented.
Each item below affects how the file is interpreted, what the physician can answer and whether additional documents are needed before a responsible response.
Primary liver cancer and liver metastases are not managed as the same diagnosis.
Treatment feasibility can be limited by liver function even when tumor burden looks treatable.
Portal vein thrombosis or vascular invasion changes specialist interpretation.
HBV/HCV control and liver inflammation affect safety planning.
Most delays happen when the diagnosis is described verbally but the file lacks dates, reports, imaging, pathology or the current specialist recommendation. The documents below are requested before the file is considered ready for review.
The page does not present a hospital visit or travel plan as automatically suitable. Any Cuba-related discussion remains conditional on physician review of the current file.
The review may require both liver function assessment and cancer treatment review.
Poor liver reserve or active complications can limit travel or treatment options.
The file does not assume all liver lesions are primary liver cancer.
International coordination should never delay emergency care. If any of the following are present, the patient should be assessed locally first.
No. It explains how the file is organized for review. Suitability, route, timing and safety can only be determined by physicians after reviewing the complete current record.
A summary helps, but it is not enough for most oncology reviews. Pathology, imaging, treatment history, lab results and the latest oncology note are usually needed.
No. Cuba Health Assist coordinates records, communication, translation support and logistics. Medical decisions remain with licensed physicians and the patient’s treating team.
The team will request missing reports before presenting the case as ready. This protects the patient from receiving a weak or unrealistic response.
No. Severe or rapidly worsening symptoms require local emergency or oncology care first. International coordination is not an emergency service.
A coordinator will organize the medical information and guide the next step according to specialist review. The process is designed to be transparent, clinically cautious and written.